Total Payments
$1.1M
2024 Payments
$14,792
Companies
26
Transactions
183
Medicare Patients
1,338
Medicare Billing
$163,051
Payment Breakdown by Category
Research$948,310 (89.7%)
Consulting$93,249 (8.8%)
Other$6,330 (0.6%)
Travel$5,108 (0.5%)
Food & Beverage$3,789 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $948,310 | 111 | 89.7% |
| Consulting Fee | $93,249 | 26 | 8.8% |
| Travel and Lodging | $5,108 | 20 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,830 | 2 | 0.4% |
| Food and Beverage | $3,789 | 23 | 0.4% |
| Honoraria | $2,500 | 1 | 0.2% |
Payments by Type
Research
$948,310
111 transactions
General
$108,475
72 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $256,025 | 7 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $238,255 | 47 | $0 (2021) |
| Hoffmann-La Roche Limited | $180,960 | 9 | $0 (2017) |
| Janssen Research & Development, LLC | $146,795 | 22 | $0 (2021) |
| F. Hoffmann-La Roche AG | $73,400 | 5 | $0 (2018) |
| Acerta Pharma LLC | $42,750 | 6 | $0 (2019) |
| EISAI INC. | $24,490 | 9 | $0 (2021) |
| Merck Sharp & Dohme LLC | $23,679 | 14 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $15,079 | 16 | $0 (2021) |
| Novartis Pharma AG | $7,800 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,792 | 7 | Merck Sharp & Dohme LLC ($9,012) |
| 2023 | $10,044 | 5 | Merck Sharp & Dohme LLC ($4,550) |
| 2022 | $5,529 | 6 | E.R. Squibb & Sons, L.L.C. ($2,700) |
| 2021 | $147,655 | 39 | Janssen Research & Development, LLC ($86,390) |
| 2020 | $147,424 | 30 | Janssen Research & Development, LLC ($58,805) |
| 2019 | $30,533 | 10 | Pharmacyclics LLC, An AbbVie Company ($13,750) |
| 2018 | $232,038 | 35 | Pharmacyclics LLC, An AbbVie Company ($94,300) |
| 2017 | $468,770 | 51 | NOVARTIS PHARMACEUTICALS CORPORATION ($192,575) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,480.00 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 08/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $302.12 | General |
| 08/12/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | Cash or cash equivalent | $69.84 | General |
| 05/07/2024 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $2,300.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 05/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,592.50 | General |
| 01/03/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,047.50 | General |
| 10/11/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 09/18/2023 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 09/18/2023 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $50.85 | General |
| 09/18/2023 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $43.41 | General |
| 05/16/2023 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 06/09/2022 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 04/28/2022 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 03/24/2022 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $200.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 03/24/2022 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $200.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 03/17/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $2,700.00 | General |
| 03/04/2022 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $129.32 | General |
| Category: Oncology | ||||||
| 12/24/2021 | EISAI INC. | Ontak (Drug) | — | Cash or cash equivalent | $2,830.00 | Research |
| Study: A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma • Category: Oncology | ||||||
| 12/09/2021 | EISAI INC. | Ontak (Drug) | — | Cash or cash equivalent | $6,240.00 | Research |
| Study: A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma • Category: Oncology | ||||||
| 12/09/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma • Category: ONCOLOGY | ||||||
| 12/09/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: A Study of PCI32765 Ibrutinib in Combination With Either Bendamustine and Rituximab or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Participants With Previously Treated Indolent Non Hodgkin Lymphoma | ||||||
| 11/19/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $26,355.00 | Research |
| Study: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||||||
| 11/18/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,935.00 | General |
| 11/03/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $9,515.00 | Research |
| Study: A Randomized Open label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the Firstline Treatment of Subjects with Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 R R CLL WITH GDC0199 BR | Hoffmann-La Roche Limited | $180,960 | 9 |
| A PHASE III OPEN LABEL RANDOMIZED MULTICENTER TRIAL OF OFATUMUMAB MAINTENANCE TREATMENT VERSUS NO FURTHER TREATMENT IN SUBJECTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA CLL WHO HAVE RESPONDED TO INDUCTION THERAPY | NOVARTIS PHARMACEUTICALS CORPORATION | $146,350 | 1 |
| PCYC-1130-CA | Pharmacyclics LLC, An AbbVie Company | $117,100 | 18 |
| PH III GDC 199 GA101 VS GCHL IN CLL WITH COMORBIDITIES | F. Hoffmann-La Roche AG | $73,400 | 5 |
| PHASE II DIFFUSE LARGE B CELL LYMPHOMA DLBCL | NOVARTIS PHARMACEUTICALS CORPORATION | $64,225 | 2 |
| A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Janssen Research & Development, LLC | $60,405 | 8 |
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $56,300 | 15 |
| PCYC-1112-CA | Pharmacyclics LLC, An AbbVie Company | $48,850 | 4 |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | Janssen Research & Development, LLC | $47,950 | 6 |
| A Randomized Open label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the Firstline Treatment of Subjects with Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL | Janssen Research & Development, LLC | $37,240 | 5 |
| A PHASE II SINGLE ARM MULTICENTER OPEN LABEL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN ADULT PATIENTS WITH REFRACTORY OR RELAPSED FOLLICULAR LYMPHOMA | Novartis Pharmaceuticals Corporation | $28,500 | 2 |
| A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma | EISAI INC. | $22,290 | 7 |
| PHASE II DIFFUSE LARGE B CELL LYMPHOMA DLBCL | Novartis Pharmaceuticals Corporation | $16,950 | 2 |
| A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | Acerta Pharma LLC | $10,040 | 1 |
| CCTL019E2202 | Novartis Pharma AG | $7,800 | 6 |
| PCYC-1121-CA | Pharmacyclics LLC, An AbbVie Company | $7,125 | 1 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | BeiGene (Suzhou) Co., Ltd. | $5,895 | 2 |
| A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenstrom's Macroglobulinemia (WM) | BeiGene, Ltd. | $5,105 | 2 |
| Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Pharmacyclics LLC, An AbbVie Company | $3,725 | 4 |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | Pharmacyclics LLC, An AbbVie Company | $1,955 | 3 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL) | BeiGene (Suzhou) Co., Ltd. | $1,710 | 2 |
| PCYC-1143-CA | Pharmacyclics LLC, An AbbVie Company | $1,600 | 1 |
| Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma | Pharmacyclics LLC, An AbbVie Company | $1,600 | 1 |
| A Study of PCI32765 Ibrutinib in Combination With Either Bendamustine and Rituximab or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Participants With Previously Treated Indolent Non Hodgkin Lymphoma | Janssen Research & Development, LLC | $1,200 | 3 |
| A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | BeiGene AUS Pty Ltd | $35.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 297 | 497 | $191,481 | $37,386 |
| 2022 | 7 | 329 | 563 | $223,046 | $45,804 |
| 2021 | 8 | 364 | 579 | $198,694 | $48,092 |
| 2020 | 10 | 348 | 510 | $130,553 | $31,768 |
Total Patients
1,338
Total Services
2,149
Medicare Billing
$163,051
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 206 | 344 | $135,602 | $26,141 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 80 | $22,240 | $5,225 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $16,655 | $2,765 | 16.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 16 | 18 | $7,182 | $1,338 | 18.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 19 | 20 | $5,400 | $1,071 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 16 | $4,402 | $845.85 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 199 | 356 | $137,909 | $28,085 | 20.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 71 | $19,738 | $4,353 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $22,462 | $3,977 | 17.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 47 | $18,753 | $3,974 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 24 | $12,342 | $2,937 | 23.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 27 | $7,054 | $1,548 | 21.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 12 | 12 | $4,788 | $929.94 | 19.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 177 | 290 | $95,596 | $24,109 | 25.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 59 | $23,541 | $5,126 | 21.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $23,291 | $5,102 | 21.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 41 | 51 | $13,581 | $4,056 | 29.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 51 | $14,178 | $3,181 | 22.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 22 | 24 | $13,404 | $3,060 | 22.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 39 | 46 | $10,508 | $2,249 | 21.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 21 | 26 | $4,595 | $1,210 | 26.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 103 | 174 | $48,178 | $11,530 | 23.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 24 | 84 | $20,328 | $5,158 | 25.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $12,696 | $2,876 | 22.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 61 | 66 | $12,149 | $2,670 | 22.0% |
About Dr. Eric Jacobsen, MD
Dr. Eric Jacobsen, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457321861.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Jacobsen, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $14,792 received in 2024. These payments were reported across 183 transactions from 26 companies. The most common payment nature is "" ($948,310).
As a Medicare-enrolled provider, Jacobsen has provided services to 1,338 Medicare beneficiaries, totaling 2,149 services with total Medicare billing of $163,051. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 01/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457321861
Products in Payments
- Ibrutinib (Drug) $186,375
- VENCLEXTA (Biological) $180,960
- ARZERRA (Drug) $146,350
- KYMRIAH (Biological) $117,475
- GAZYVA (Biological) $73,400
- CALQUENCE (Drug) $49,751
- Imbruvica (Drug) $44,600
- Ontak (Drug) $24,490
- Non-Covered $12,857
- BRUKINSA (Drug) $12,710
- IMBRUVICA (Drug) $7,280
- SGN35 (Biological) $4,053
- Tazverik (Drug) $3,480
- Copiktra (Drug) $2,833
- Aliqopa (Drug) $2,223
- THYMOGLOBULIN (Biological) $350.00
- Lumoxiti (Drug) $340.00
- KEYTRUDA (Biological) $150.00
- LYNPARZA (Drug) $129.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795
Amir Fathi, M.d, M.D
Hematology & Oncology — Payments: $548,854
Hematology & Oncology $548,854